The House Energy and Commerce Subcommittee on Health today held a hearing to discuss four bills aimed at making prescription drugs more affordable for Americans. “It is time for Congress to take bold and decisive action to reduce prescription drug prices for all Americans,” said Energy and Commerce Committee Chairman Frank Pallone, D-N.J. Among other bills, the subcommittee discussed the Lower Drug Costs Now Act of 2019 (H.R. 3). Introduced last week by House Democratic leaders, the bill would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs, including allowing the Department of Health and Human Services to negotiate directly with drug manufacturers the price of at least 25 — and up to 250 — brand-name prescription drugs that lack price competition in the market. Witnesses at the hearing were from Baldwin Wallace University, Johns Hopkins Bloomberg School of Public Health and American Enterprise Institute.
 

Related News Articles

Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Chairperson's File
Public
This month Congress enacted the One Big Beautiful Bill Act — a sweeping package that contained many of President Trump’s legislative priorities on taxes,…
Headline
The AHA July 2 expressed support for the Resident Physician Shortage Reduction Act (H.R. 3890), bipartisan legislation that would add 14,000 Medicare-funded…